接受经皮冠状动脉介入治疗的患者使用阿昔单抗和依替巴肽后血小板减少症的发生率及病程

Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.

作者信息

Fahdi Ibrahim E, Saucedo Jorge F, Hennebry Thomas, Ghani Mohammad, Sadanandan Saihari, Garza-Arreola Luis

机构信息

University of Arkansas School for Medical Sciences, Little Rock, Arkansas, USA.

出版信息

Am J Cardiol. 2004 Feb 15;93(4):453-5. doi: 10.1016/j.amjcard.2003.10.041.

DOI:10.1016/j.amjcard.2003.10.041

PMID:14969621

Abstract

Thrombocytopenia is recognized as a potential adverse effect in patients treated with glycoprotein IIb/IIIa inhibitors. We monitored platelet counts at baseline and at 10 minutes and at 1, 8, and 24 hours after initiation of therapy with either abciximab (n = 74) or eptifibatide (n = 26) in a series of 100 consecutive patients who underwent percutaneous coronary intervention. Thrombocytopenia (platelet count <100,000 m(3) occurred in 11 patients treated with abciximab (15%) and in none of those treated with eptifibatide. The inhibition of platelet adhesion to fibrinogen-coated material by abciximab and eptifibatide was similar, indicating that the reduction in platelet count with abciximab is unrelated to inhibition of platelet function.

摘要

血小板减少症被认为是接受糖蛋白IIb/IIIa抑制剂治疗的患者的一种潜在不良反应。在一系列连续100例接受经皮冠状动脉介入治疗的患者中，我们在基线时以及在用阿昔单抗（n = 74）或依替巴肽（n = 26）开始治疗后的10分钟、1小时、8小时和24小时监测血小板计数。接受阿昔单抗治疗的11例患者（15%）出现血小板减少症（血小板计数<100,000/mm³），而接受依替巴肽治疗的患者无一出现。阿昔单抗和依替巴肽对血小板黏附于纤维蛋白原包被材料的抑制作用相似，这表明阿昔单抗导致的血小板计数降低与血小板功能抑制无关。